At a glance
- Originator Pfizer
- Class Small molecules
- Mechanism of Action Purine nucleoside phosphorylase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Immunological disorders; Transplant rejection
Most Recent Events
- 19 Apr 1996 Immunological Disorders section added to drug profile.
- 19 Apr 1996 Discontinued-I for Immunological disorders in USA (PO)